Really good read about the risks involved when considering compounded medications like semaglutide for patients. I will later link ADA and other major medical organizations message to clinicians and patients what to look out for as this should be a last resort IMO (I.e., shortage, standard too expensive for a patient who’s BMI is > 30, etc)
Hims & Hers' stock dips: a wake-up call for telehealth? 📉 Last week, Hims & Hers’ stock dropped over 20% after the FDA resolved the semaglutide shortage—effectively shutting down the legal sale of compounded weight-loss meds like Ozempic and Wegovy. This shake-up raises big questions about regulatory risks, revenue stability, and the future of DTC (direct-to-consumer) healthcare. This isn’t just about one company. It’s a reminder that in healthcare, there are no shortcuts. Read Dr. Aditi U Joshi's full analysis here: https://lnkd.in/geXdtNwc What are your thoughts on the future of telehealth? Drop them in the comments! 👇 #Telehealth #HealthTech #DigitalHealth #HimsAndHers
